Core Scientific, Inc./tx - CS (CORZR)

CUSIP: 21874A122

Q1 2024 13F Holders as of 31 Mar 2024

Share change
+57,477
SEC-reported price per share
$0.80
Indexed holders
1
Value change
+$45,982
Number of buys
1

Security key

21874A122

Report period

Q1 2024

Indexed institutions

1

Top holders

1

Ownership snapshot

Top reported holders of CORZR - Core Scientific, Inc./tx - CS (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Darin Feinstein
Disclosed value leader
Darin Feinstein
Comparable rows
0/7
Latest evidence
23 Jan 2024
3/4/5 Highest disclosed value: $58,662,578 7 rows are not safely comparable across share classes. Showing 1-6 of 7 holder rows.

Quick read

Darin Feinstein has the largest disclosed position value at $58.66M.

0 of 7 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Darin Feinstein's linked filing trail.
Disclosed position value Top 5
Darin Feinstein $58.66M
Michael J. Levitt $22.44M
Matt Minnis $54.29M
Jarvis V Hollingsworth $1.89M
Dr. Kneeland Youngblood $373K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 7 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Darin Feinstein
3/4/5
Director, 10%+ Owner
—
mixed-class rows
$58,662,578
18,604,669 shares
mixed-class rows
— 23 Jan 2024
Michael J. Levitt
3/4/5
Director, 10%+ Owner
—
mixed-class rows
$22,439,129
8,131,149 shares
mixed-class rows
— 23 Jan 2024
Matt Minnis
3/4/5
Director
—
mixed-class rows
$54,287,309
16,768,580 shares
mixed-class rows
— 23 Jan 2024
Jarvis V Hollingsworth
3/4/5
Director
—
mixed-class rows
$1,887,057
591,019 shares
mixed-class rows
— 23 Jan 2024
Dr. Kneeland Youngblood
3/4/5
Director
—
mixed-class rows
$372,998
132,870 shares
mixed-class rows
— 23 Jan 2024
Brian Neville
3/4/5
Chief Accounting Officer
—
denominator unverified
$63,022
450,154 shares
— 19 Sep 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
1
Shares
57,477
Indexed holders
1
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2024 vs Q3 2024 Across Filers

Q3 2024 indexed holders
1
Q1 2024 indexed holders
1
Indexed holder difference
0
Investor Q3 2024 Shares Q1 2024 Shares Share Diff Share Chg % Q3 2024 value Q1 2024 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .